Phase 3 N=139 PinPointe FootLaser for the Treatment of Onychomycosis
Infected Toenails · Onychomycosis
Primary: Nail Bed Clearing
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail
Onychomycosis
Primary: Treatment Related Adverse Events — 22; 8 Participants
Phase 4 N=132 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules
Onychomycosis, Toe
Primary: Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 5 — 25.6 percentage of participants
Phase 2 N=47 Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail
Onychomycosis
Primary: Number of Participants With Negative Fungal Culture — 14; 2 Participants
N/A N=5 Early Feasibility Study to Evaluate the Efficacy of the RenewalNail™ Plasma Treatment System in Patients With Onychomycosis (Fungal Nail)
Onychomycosis of Toenail · Onychomycosis
Primary: Mycological Cure — 2 Participants
N/A N=105 Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus
Onychomycosis
Primary: Proportion of Toenails Attaining 25 Percent (%) or More Increase in Clear Nail — 65 percentage of toenails
N/A N=26 Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)
Onychomycosis Due to Trichophyton Rubrum · Onychomycosis Due to Trichophyton Mentagrophytes
Primary: Mycological Cure — 12 Participants
Phase 3 N=518 Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
Onychomycosis
Primary: Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks. — 0.79; 0.78; 1.47; 0.00 Percentage of Participants
Phase 3 N=526 Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
Onychomycosis
Primary: Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks — 1.50; 0.77; 2.96; 0 Percentage…
N/A N=109 Study of Erchonia Low Level Laser Light Therapy to Treat Toenail Fungus
Onychomycosis
Primary: Number of Toenails Attaining 3 Millimeters (mm) or More of Clear Nail Growth — 134 toenails
N/A N=126 Light Therapy for Onychomycosis Study
Onychomycosis of Toenail
Primary: An Increase in Healthy New Nail Growth Free of Fungal Infection ("Clear Nail") at 12 Months Post-treatment — 5.9; 5.5 millimeters (mm)
Phase 2 N=20 Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot
Tinea Pedis
Primary: Number of Participants With Complete Cure: Post Treatment (Day 17) — 0; 4 Participants
N/A N=182 Less Infections for the Diabetic Foot
Diabetic Foot
Primary: Number of Participants Experiencing Clinical Failure — 26; 30 Participants
Phase 4 N=20 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer
Foot Dermatoses
Primary: Percent of "in Label" Adherent Subjects — 85; 60 percentage of participants
Phase 3 N=1,381 Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.
Onychomycosis
Primary: Clinical and Mycological Cure of Target Toenail — 22.3; 1 Percentage of participants — p=<0.001
Phase 3 N=40 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients
Onychomycosis
Primary: Primary Endpoint - Efficacy — 4 Participants
Phase 2 N=29 Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
Onychomycosis
Primary: Clinical Evidence of Complete Clearance of the Treatment-targeted Great Toenail Plus a Negative Fungal Culture at Day 360 — 2; 27 participants
Phase 4 N=50 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish
Foot Dermatoses
Primary: Measurement of Antifungal Activity of Loceryl Nail Lacquer — 53.6; 53.5 Milimeter
Phase 3 N=604 Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
Onychomycosis of Toenails
Primary: Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52 — 36; 3; 360; 202 participants — p=<0.001
N/A N=54 A Retrospective Analysis of the Effects of Low Level Laser Therapy on Toenail Onychomycosis
Onychomycosis
Primary: Percent (%) of Toenails Attaining 3 Millimeters (mm) or More of Clear Nail Growth — 67 Percent of Toenails
Phase 4 N=55 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
Onychomycosis · Tinea Unguium
Primary: Number of Participants With Local Tolerability Reactions by Severity — 54; 0; 1; 0 Participants
Phase 3 N=594 Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
Onychomycosis of Toenails
Primary: Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52 — 26; 1; 373; 193 participants — p=0.001
Phase 3 N=1,029 Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis
Onychomycosis
Primary: Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks — 1.18; 0.96 Percentage of participants
Phase 4 N=13 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish
Onychomycosis of Toenail
Primary: Percentage of Nail Polish Disruption Using the Likert Scale — 0.6; 0 percentage of nail polish disruption
Phase 2 N=218 A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)
Onychomycosis
Primary: Complete Cure of Onychomycosis at Week 48. — 8; 20; 15; 7 Participants — p=0.005
Phase 2 N=582 Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis
Onychomycosis
Primary: The Percentage of Participants Who Achieve Effective Treatment at Week 52 — 54; 38; 29; 21 Percentage of participants — p=<0.001
Phase 3 N=855 Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Tinea Pedis
Primary: Complete Cure of Interdigital Tinea Pedis — 16.8; 1.7 percentage of subjects — p=<0.025
Phase 2 N=259 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail
Onychomycosis
Primary: The Proportion of Subjects in the Intent-to-treat Population With Complete Cure, Defined as Clinical AND Mycological Cure, at Week 48 — 17; 19; 22; 18 Participants
Phase 3 N=707 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis
Tinea Pedis · Athlete's Foot
Primary: Percentage of Subjects With Complete Cure at Week 6. — 17.7; 7.1; 16.1; 3.1 percentage of subjects with complete cur — p=0.010
N/A N=8 308nm Excimer Laser for Treatment of Fingernail Psoriasis
Nail Psoriasis
Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale